Firebrick receives $250,000 R&D Tax Incentive
Open PDF
| Stock | Firebrick Pharma Ltd (FRE.ASX) |
|---|---|
| Release Time | 10 Sep 2025, 8:26 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Firebrick receives $250,000 R&D Tax Incentive
Key Points
- Firebrick Pharma receives $250,000 R&D Tax Incentive payment
- Incentive related to $576,000 in reported R&D costs in FY25
- Funds will support further development of Nasodine and new product development
Full Summary
Firebrick Pharma Limited (ASX:FRE) has announced that it has received an RDTI (R&D Tax Incentive) payment of $250,000 for eligible R&D expenditure incurred in 2024/25. The incentive payment related to $576,000 in reported R&D costs in the FY25 year, associated with the Company's further development of Nasodine as a broad spectrum antimicrobial agent and other new product development. Dr Peter Molloy, Executive Director of Firebrick Pharma, welcomed the 'valuable injection of non-dilutive funds from the R&D tax incentive', which will support the company's ongoing research and development activities.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In